Shots:

• The P-IIIb FOCUS study involves assessing of fremanezumab (quarterly & monthly) vs PBO in patients in a ratio (1:1:1) with episodic/chronic migraine (EM/CM) prior treated with two to four classes of preventive therapy
• The P-IIIb FOCUS study results: @3mos. reduction in monthly migraine days; reduction in migraine-related symptoms; improvement in disability & QOL; improvements in depression status; work productivity and activity impairment
• Fremanezumab (TEV-48125) is a mAb targeting CGRP- thus preventing its binding to receptors and has received approval in the US & EU on Sept’2018 & Apr’2019 respectively

Click here to read full press release/ article | Ref: Teva | Image:  Rasayanika